Targeting melanocortin receptors for the treatment of obesity

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 4, 2006, Pages 569-576

  Markison, Stacy ^a   Foster, Alan C ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOUTI RELATED PROTEIN INHIBITOR; ALPHA INTERMEDIN; ANTIDIABETIC AGENT; MELANOCORTIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 3 RECEPTOR AGONIST; MELANOCORTIN 3 RECEPTOR ANTAGONIST; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 4 RECEPTOR AGONIST; MELANOCORTIN RECEPTOR; PIPERAZINE DERIVATIVE; SYNDECAN 3 INHIBITOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; BODY WEIGHT; BRAIN FUNCTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; FEEDING BEHAVIOR; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GROWTH RETARDATION; HUMAN; NEUROANATOMY; NONHUMAN; OBESITY; PENIS ERECTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; TACHYPHYLAXIS;

EID: 33846170050     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.10.011     Document Type: Review

References (68)

1. Foster A.C., et al. MC4 receptor antagonists: a potential treatment for cachexia. IDrugs 8 (2005) 314-319
2. Deboer M.D., and Marks D.L. Cachexia: lessons from melanocortin antagonism. Trends Endocrinol. Metab. 17 (2006) 199-204
3. Cone R.D. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 8 (2005) 571-578
4. Jobst E.E., et al. The electrophysiology of feeding circuits. Trends Endocrinol. Metab. 15 (2004) 488-499
5. Gropp E., et al. Agouti-related peptide-expressing neurons are mandatory for feeding. Nat. Neurosci. 8 (2005) 1289-1291
6. Luquet S., et al. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 310 (2005) 683-685
7. Cowley M.A., Chen C., et al. Estrogen transiently increases delayed rectifier, voltage-dependent potassium currents in ovine gonadotropes. Neuroendocrinology 69 (1999) 254-260
8. Balthasar N., et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123 (2005) 493-505
9. Sheng G., et al. Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior. Nat. Med. 12 (2006) 526-533
10. Cowley M.A., et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411 (2001) 480-484
11. van den Top M., et al. Orexigen-sensitive NPY/AgRP pacemaker neurons in the hypothalamic arcuate nucleus. Nat. Neurosci. 7 (2003) 493-494
12. Cowley M.A., et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 37 (2003) 649-661
13. Plum L., et al. Enhanced PIP(3) signaling in POMC neurons causes K(ATP) channel activation and leads to diet-sensitive obesity. J. Clin. Invest. 116 (2006) 1886-1901
14. Ibrahim N., et al. Hypothalamic proopiomelanocortin neurons are glucose responsive and express K(ATP) channels. Endocrinology 144 (2003) 1331-1340
15. Sternson S.M., et al. Topographic mapping of VMH → arcuate nucleus microcircuits and their reorganization by fasting. Nat. Neurosci. 8 (2005) 1356-1363
16. Heisler L.K., et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 51 (2006) 239-249
17. Heisler L.K., et al. Activation of central melanocortin pathways by fenfluramine. Science 297 (2002) 609-611
18. Pinto S., et al. Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science 304 (2004) 110-115
19. Jegou S., et al. Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus. J. Neuroendocrinol. 12 (2000) 501-505
20. Mounien L., et al. Expression of melanocortin MC3 and MC4 receptor mRNAs by neuropeptide Y neurons in the rat arcuate nucleus. Neuroendocrinology 82 (2005) 164-170
21. Marks D.L., et al. The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R). Peptides 27 (2006) 259-264
22. Fan J., et al. Correlation between hepatic fat, lipid peroxidation and hepatic fibrosis in rats chronically fed with ethanol and/or high fat diet. Zhonghua Nei Ke Za Zhi 36 (1997) 808-811
23. Grill H.J., et al. Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight. J. Neurosci. 18 (1998) 10128-10135
24. Hamilton B.S., and Doods H.N. Chronic application of MTII in a rat model of obesity results in sustained weight loss. Obes. Res. 10 (2002) 182-187
25. Li G., et al. Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression. J. Endocrinol. 182 (2004) 123-132
26. Palucki B.L., et al. Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-pipe ridinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarbo xamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett. 15 (2005) 171-175
27. Ye Z., et al. Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]- 1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicycl o[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. Bioorg. Med. Chem. Lett. 15 (2005) 3501-3505
28. Yaswen L., et al. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat. Med. 5 (1999) 1066-1670
29. Lu D., et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 371 (1994) 799-802
30. Graham M., et al. Overexpression of Agrt leads to obesity in transgenic mice. Nat. Genet. 17 (1997) 273-274
31. Ollmann M.M., et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278 (1997) 135-138
32. Shutter J.R., et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev. 11 (1997) 593-602
33. Huszar, D., et al., Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88, 131-41.
34. Krude H., et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J. Clin. Endocrinol. Metab. 88 (2003) 4633-4640
35. Santoro N., et al. Weight loss in obese children carrying the proopiomelanocortin R236G variant. J. Endocrinol. Invest. 29 (2006) 226-230
36. Farooqi I.S., and O'Rahilly S. New advances in the genetics of early onset obesity. Int. J. Obes. (Lond.) 29 (2005) 1149-1152
37. Yeo G.S., et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat. Genet. 20 (1998) 111-112
38. Vaisse C., et al. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat. Genet. 20 (1998) 113-114
39. Farooqi I.S., et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N. Engl. J. Med. 348 (2003) 1085-1095
40. MacKenzie R.G. Obesity-associated mutations in the human melanocortin-4 receptor gene. Peptides 27 (2006) 395-403
41. Lubrano-Berthelier C., et al. Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum. Mol. Genet. 12 (2003) 145-153
42. Tao Y.X., and Segaloff D.L. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. J. Clin. Endocrinol. Metab. 90 (2005) 5632-5638
43. Tao Y.X., and Segaloff D.L. Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. Endocrinology 144 (2003) 4544-4551
44. Sawyer T.K., et al. 4-Norleucine, 7-d-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. U S A 77 (1980) 5754-5758
45. Al-Obeidi F., et al. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J. Med. Chem. 32 (1989) 2555-2561
46. Bednarek M.A., et al. Potent and selective peptide agonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. Biochem. Biophys. Res. Commun. 286 (2001) 641-645
47. Sebhat I.K., et al. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J. Med. Chem. 45 (2002) 4589-4593
48. Todorovic A., and Haskell-Luevano C. A review of melanocortin receptor small molecule ligands. Peptides 26 (2005) 2026-2036
49. Nargund R.P., et al. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J. Med. Chem. 49 (2006) 4035-4043
50. Mountjoy K.G., et al. Melanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells. Physiol. Genom. 5 (2001) 11-19
51. Vongs A., et al. Activation of MAP kinase by MC4-R through PI3 kinase. Regul. Pept. 120 (2004) 113-118
52. Daniels D., et al. Melanocortin receptor signaling through mitogen-activated protein kinase in vitro and in rat hypothalamus. Brain Res. 986 (2003) 1-11
53. Konda Y., et al. Interaction of dual intracellular signaling pathways activated by the melanocortin-3 receptor. J. Biol. Chem. 269 (1994) 13162-13166
54. Nickolls S.A., et al. Functional selectivity of melanocortin 4 receptor peptide and non-peptide agonists: evidence for ligand-specific conformational states. J. Pharmacol. Exp. Ther. 313 (2005) 1281-1288
55. Chen A.S., et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 26 (2000) 97-102
56. Butler A.A. The melanocortin system and energy balance. Peptides 27 (2006) 281-290
57. Tao Y.X. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol. Cell Endocrinol. 239 (2005) 1-14
58. Bagnol D., et al. Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. J. Neurosci. 19 (1999) RC26
59. Arasasingham P.N., et al. Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: antagonists for the AGRP/melanocortin receptor binding. J. Med. Chem. 46 (2003) 9-11
60. Reizes O., et al. Transgenic expression of syndecan-1 uncovers a physiological control of feeding behavior by syndecan-3. Cell 106 (2001) 105-116
61. Reizes O., et al. A role for syndecan-3 in the melanocortin regulation of energy balance. Peptides 27 (2006) 274-280
62. Creemers J.W., et al. Agouti-related protein is posttranslationally cleaved by proprotein convertase 1 to generate agouti-related protein (AGRP)83-132: interaction between AGRP83-132 and melanocortin receptors cannot be influenced by syndecan-3. Endocrinology 147 (2006) 1621-1631
63. Dyck B., et al. Aryl piperazine melanocortin MC4 receptor agonists. Bioorg. Med. Chem. Lett. 13 (2003) 3793-3796
64. Richardson T.I., et al. Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor. J. Med. Chem. 47 (2004) 744-755
65. Xi N., et al. Synthesis of novel melanocortin 4 receptor agonists and antagonists containing a succinamide core. Bioorg. Med. Chem. Lett. 14 (2004) 377-381
66. Ujjainwalla F., et al. Design and syntheses of melanocortin subtype-4 receptor agonists: evolution of the pyridazinone archetype. Bioorg. Med. Chem. Lett. 13 (2003) 4431-4435
67. Pan K., et al. 2,3-Diaryl-5-anilino[1,2,4]thiadiazoles as melanocortin MC4 receptor agonists and their effects on feeding behavior in rats. Bioorg. Med. Chem. 11 (2003) 185-192
68. Fotsch C., et al. Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamides. Bioorg. Med. Chem. Lett. 15 (2005) 1623-1627